Emergent BioSolutions (EBS) Tops Q4 EPS by 48c, Revenues Beat; Offers FY21 Revenue Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/23/2026

1. USO
2. NVDA
3. META
4. SPY
5. MSFT
6. DCOY
7. VKTX
8. PRGS
9. WOR
10. LGND

Go back to Emergent BioSolutions (EBS) Tops Q4 EPS by 48c, Revenues Beat; Offers FY21 Revenue Guidance Above Consensus

Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020

February 18, 2021 4:05 PM EST

Reports record fourth quarter and year to date 2020 performance, in line with prior guidanceReaffirms full year 2021 forecast

GAITHERSBURG, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2020. The Company also reaffirmed its full year 2021 forecast.

Emergents financial and operational performance in 2020 reflects the impact we are making in addressing the growing public health threat landscape and meeting our mission to protect and enhance the lives of patients, said Robert G. Kramer, president and CEO of... More